Quantum Materials Corp Business Updates | Your Money



San Marcos, TX, November 24th, 2021 (GLOBE NEWSWIRE) – Quantum Materials Corp (QMC) announces the latest business developments.

Quantum Materials Corp, a Nevada company, has initiated a declaration of consent solicitation (the “Declaration of Consent”) in order to obtain written consent from shareholders of the Company to approve and approve an amendment (the “Amendment bylaws”) to the Articles of Association of Obtain Company Increase the number of approved common shares with a par value of $ 0.001 per share from 750,000,000 to 2,000,000,000. August 2, 2021 was set as the record date for determining the shareholders entitled to consent. Shareholders who made up the majority of the voting rights of the company’s outstanding ordinary shares as of the balance sheet date were classified as entitled to consent so that the shareholder representative can approve the shareholder vote.The date on which the declaration of consent was obtained was August 30, 2021.

To count, a properly completed and executed “Action with Written Consent” form must be received by the Company or its agents by October 30, 2021 at 5:00 p.m. daylight saving time (the “Expiration Date”), subject to early termination or extension of the expiration date Company’s discretion. As of the expiration date, the company’s representatives had received a total of 378,723,614 votes, of which 367,461,168, or 52.2% of eligible shareholders, voted to confirm the increase in authorized common stock. The company changed the articles of association with the approval of the shareholders.

The company currently intends to file an application to become a filing issuer with the SEC and to resume filings with the SEC at the earliest opportunity. In this regard, the company is working carefully with its accountants and securities advisors to compile, disseminate, and review the financial and other current information that must be presented in its public filings, and to prepare and submit a registration statement in order to re-report become an exhibitor. Thereafter, and subject to all regulatory approvals, it will attempt to trade its common stock on the OTC market again.

On November 16, 2021, the company was notified by its auditing firm, RBSM, LLP, that the company had completed the audit of the 2020 financial year. The current year 2021 audit for the company is ongoing. RBSM recently opened an office in Austin, Texas that is expected to expedite the completion of this audit.

The company looks forward to closing its filing with the SEC and resuming trading in the company’s common stock.

About Quantum Materials Corp

At Quantum Materials, our scientists and engineers believe in the power of innovation to improve lives and solve critical problems in our world. Our team consists of experts in the fields of quantum materials, nanotechnology, biochemical and chemical assays and counterfeit security. Bringing groundbreaking ideas to life and developing new solutions inspires our work. For more information, visit Quantum Materials Corp at www.quantummaterialscorp.com Quantum Materials Corp, Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements about plans, goals, intentions and expectations with regard to future financial results, events, operations, services, product development and potential, and statements about future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. While the management of Quantum Materials Corp believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements involve various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Quantum Materials Corp., which could cause actual results and developments to differ materially from those expressed, implied or projected in the forward-looking information and statements. These risks and uncertainties include but are not limited to the uncertainties in research and development, future clinical data and analysis, including post-marketing, decisions by regulatory agencies such as the FDA or the EMA as to whether and when a drug, device, or biological application should be approved that may be submitted for such product candidates, as well as their labeling decisions and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates, if approved, may not be commercially successful, the future Approval and commercial success of therapeutic alternatives, Quantum Materials Corp’s ability to benefit from external growth opportunities, complete related transactions and / or obtain regulatory approvals, intellectual property risks tum and related pending or future litigation and the final outcome of such litigation, exchange rate trends and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereof, and the effects COVID-19 has on us, our customers, suppliers, and suppliers other business partners and the financial condition of each of them, our employees and the global economy as a whole. Any material impact of COVID-19 on any of the foregoing could also adversely affect us. This situation is changing rapidly and there may be additional effects not currently known to us that worsen other previously identified risks. Except as required by law, Quantum Materials Corp assumes no obligation to update or revise any forward-looking information or statements. Media contact: Amber Lane amber.lane@quantummaterialscorp.com

Copyright 2021 GlobeNewswire, Inc.